• PDX MODELS
• FDA
• COMPANION DRUGS
• IMMUNOTHERAPY
• BOTANICAL
HOW NEW DEVELOPMENT MODELS CAN LEAD TO CANCER BREAKTHROUGHS by Dan Dupuis
The pharmaceutical industry’s long and successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters, worked well for many years, but its R&D productivity has now plummeted and the environment is changing. Read More…
NEW DRUGS ON THE HORIZON 2018 by Dan Dupuis
There are a number of new drugs in late stage trials that may soon become available to patients suffering from a wide array of either life threatening diseases or conditions that significantly affect a person’s quality of life. Read More…
CAN A NEW DEVELOPMENT MODEL PREVENT COSTLY PHASE III DRUG DEVELOPMENT FAILURES? by Dan Dupuis
Attaining FDA approval for a new drug is certainly the ultimate goal of any drug research initiative. Accelerating that process can not only prove to be beneficial to patients, but is also a key component of increasing the return on investment for any entity that has a vested interest in a new medication. Read More…
A NEW STUDY FOCUSES ON A BREAKTHROUGH IMMUNO-ONCOLOGY DRUG COMBINATION by Dan Dupuis
A number of immuno-therapies formulations for the treatment of cancer have been developed in a quest to extend patient survival rates, while also mitigating life-altering side effects and safety concerns. While no current or proposed drug can make this claim, a recently published study that was featured in the British Journal of Cancer provides data that indicates that the initial promise of immunotherapies has been realized. Read More…
RESEARCH TEAM DISCOVERS DRUG COMPOUND THAT STOPS CANCER CELLS FROM SPREADING
Fighting cancer means killing cancer cells. However, oncologists know that it’s also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature Communications, shows that it may be possible to freeze cancer cells and kill them where they stand. Read More…
EXISTING DRUG MAY HELP TO TREAT BRAIN CANCER by Maria Cohut
Glioblastoma is an aggressive brain cancer that progresses very rapidly and often becomes treatment resistant. The commonest chemotherapy drug used to treat glioblastoma, temozolomide, tends not to be as effective as one might hope. But could a common altitude sickness drug enhance its success? Read More…
4 DRUG AND BIOTECH STOCKS AWAITING FDA APPROVAL IN JULY 2018 by Kinjel Shah
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year. Read More…
HOW CAN OBESITY BOTH FUEL TUMOR GROWTH AND HELP NEW IMMUNOTHERAPY DRUGS WORK BETTER?
Two new studies have provided compelling insights into the relationship between obesity and cancer. The research reveals fascinatingly paradoxical effects, suggesting obesity can suppress our immune responses to enhance tumor growth, but also improve the efficacy of a new kind of cancer-killing immunotherapy. READ MORE…
Argentum Pharmaceuticals wins patent invalidation trial against the sole remaining patent protecting Janssen’s Zytiga.
The U.S. Patent & Trademark Office (PTO) issued a final written decision Wednesday in Argentum Pharmaceuticals LLC’s inter partes review (IPR) against the sole unexpired patent covering Janssen Oncology, Inc.’s Zytiga (abiraterone acetate). Janssen Oncology is a subsidiary of Johnson & Johnson. READ MORE…
NATURALLY OCCURRING PRODUCTS IN CANCER THERAPY
Natural products have been used for the treatment of various diseases and are becoming an important research area for drug discovery. These products, especially phytochemicals have been extensively studies and have exhibited anti-carcinogenic activities by interfering with the initiation, development and progression of cancer through the modulation of various mechanisms including cellular proliferation, differentiation, apoptosis, angiogenesis, and metastasis. This concept is gaining attention because it is a cost-effective alternative to cancer treatment. READ MORE…
THIS NEW, FDA-APPROVED SKIN CARE DRUG COULD HELP OVER 7.5 MILLION PEOPLE
Alleviating psoriasis symptoms has been a difficult feat to achieve for decades, but with new advances in the skin care industry, doctors are excited that a cure may be closer than ever before. While we still haven’t reached a final remedy yet, a new advancement in the treatment of psoriasis has people super excited. Bryhali Lotion 0.01% is a new topical treatment that uses an active ingredient called halobetasol to treat the condition. And as Allure reports, Bryhali Lotion has just been approved by the Food and Drug Administration, making doctors and patients alike excited to give the new medication a try. READ MORE…
ARE BOTANICAL DRUGS THE “NEXT BIG THING” IN PHARMACEUTICALS?
Almost all new drug development is on a quest to deliver maximum efficacy, while being not only safe, but well tolerated due to exhibiting few side effects. Anyone that has brought a prescription home from the pharmacy or listened to the warnings listed at the conclusion of any drug advertisement on television realizes that all conventional drugs have a long list of warnings about the dangers and side effects that are inherent to all medications. READ MORE…